Selumetinib Sulfate

DRUG11 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Ann Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaBorderline Ovarian Serous Tumor

Phase 1

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Active, not recruitingNCT01364051

National Cancer Institute (NCI)Metastatic Melanoma, Refractory Malignant Solid Neoplasm, Stage IV Cutaneous Melanoma AJCC v6 and v7 +1

Start: 2011-05-25End: 2027-03-31Updated: 2026-04-03

Phase 2

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

CompletedNCT00551070

National Cancer Institute (NCI)Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma +3

Start: 2007-12-17End: 2020-11-13Updated: 2020-12-03

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

CompletedNCT02839720

National Cancer Institute (NCI)Cutaneous Neurofibroma, Neurofibromatosis Type 1, Optic Nerve Glioma

Start: 2017-08-26End: 2023-08-31Updated: 2023-12-06

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

CompletedNCT03040986

National Cancer Institute (NCI)KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7

Start: 2017-07-21End: 2020-10-15Updated: 2021-02-09

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Active, not recruitingNCT03155620

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma +42

Start: 2017-07-31End: 2027-01-06Updated: 2026-02-10

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

CompletedNCT03213691

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma +8

Start: 2017-10-30End: 2024-12-31Updated: 2025-02-05

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

RecruitingNCT05554328

National Cancer Institute (NCI)Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma +1

Start: 2023-04-25End: 2028-10-01Target: 165Updated: 2026-04-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

RecruitingNCT05564377

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 +12

Start: 2023-04-07End: 2030-07-01Target: 2900Updated: 2026-04-03

Phase 3

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Active, not recruitingNCT03871257

National Cancer Institute (NCI)Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma

Start: 2020-01-15End: 2027-12-31Target: 165Updated: 2026-04-03

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

RecruitingNCT04166409

National Cancer Institute (NCI)Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Astrocytoma +3

Start: 2020-01-31End: 2030-12-31Target: 170Updated: 2026-04-03

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

Active, not recruitingNCT04576117

National Cancer Institute (NCI)Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma +2

Start: 2021-02-16End: 2026-12-30Target: 300Updated: 2026-04-03

Related Papers

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib

JAMA Dermatology2025-02-262 citations

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

The Oncologist2024-05-306 citations

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort.

2024-01-258 citations

Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort.

Journal of Clinical Oncology2024-01-20

Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.

Journal of Clinical Oncology2023-06-013 citations

Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.

2022-06-077 citations

Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers

The Oncologist2022-04-1445 citations

The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

Cancer Discovery2022-03-16143 citations

Abstract 631: Germline cancer predisposition results from the National Cancer Institute - Children's Oncology Group (NCI-COG) Pediatric MATCH Trial

Cancer Research2021-07-01

Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.

Journal of Clinical Oncology2021-05-203 citations

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

Journal of Clinical Oncology2021-05-202 citations

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS<sup>G12R</sup>-mutant pancreatic ductal adenocarcinoma.

2021-01-0628 citations

Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.

Journal of Clinical Oncology2019-05-2032 citations

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study.

2012-12-21282 citations